TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Acute Effect of Hypericum Perforatum on Short-Term Memory in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adults 18 to 40 years old.~Exclusion Criteria:~* 1. Demographics: Under 18 years of age or older than 40; pregnant or nursing women; non-fluent Hebrew speakers.~  2. Body weight: less than 50 kg and more than 90 kg (to ensure effective drug dosage).~  3. Mental health: Diagnosed with any DSM-V disorder (including ADHD, learning disabilities). These DSM-V disorders may be included in the research: sexual dysfunctions, sleeping disorders and mild-moderate anxiety disorders.~  4. Any motor disability hampering a participant's ability to perform the experimental task.~  5. Consumption of any psychoactive substance within the last 72 hours. 6. Ongoing medical problems or use of any substances (e.g., other prescribed medications) which may interact negatively with any of the three drugs used in the experiment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Hypericum perforatum (Remotiv, 250 mg) (Type: EXPERIMENTAL): None
- Hypericum perforatum (Remotiv, 500 mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatient or outpatient hematology patient receiving one of the following regimens:~* Chemotherapy for hematologic malignancy:~* ABVD~* ICE ± R~* 7+3~* Conditioning therapy for stem cell transplantation:~* BEAM~* Bu/Cy ± ATG~* Bu/Flu ± ATG~* FluCy ± ATG~* FluCy + TBI~* BuMel~* FluBuCy~* Melphalan~* Etoposide + TBI~* Cyclophosphamide + TBI~Exclusion Criteria:~* Allergy to olanzapine~* Documented nausea or vomiting ≤24 hours prior to enrollment~* Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to enrollment or planned during protocol therapy~* Chronic alcoholism~* Pregnant~* Declined or unable to provide an informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triplet Therapy Plus Placebo (Type: PLACEBO_COMPARATOR): All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
- Triplet Therapy Plus Olanzapine (Type: ACTIVE_COMPARATOR): All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects ages 18 to 70 years~* HCV-Infected Genotype 1 Null responders to current standard of care~* Expansion Cohorts A1 and A2 are restricted to patients infected with HCV Genotype 1b only.~Exclusion Criteria:~* Evidence of a medical condition associate with chronic liver disease other than HCV~* History of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis~* History of Cancer within 5 years of enrollment~* History of gastrointestinal disease or surgical procedure (except Cholecystectomy)~* History of clinically significant cardiac disease~* History of Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Documented cirrhosis within 12 months prior to dosing~* Positive for Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV)~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Sentinel A (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
- Arm 2: Sentinel B (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
- Arm 3: Expansion A1 (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
- Arm 4: Expansion A2 (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
- Arm 5: Expansion B1 (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
- Arm 6: Expansion B2 (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
- Arm 7: Expansion B3 (Type: EXPERIMENTAL): BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects of reproductive potential test negative for pregnancy and agree to use appropriate contraception~* Subject is in good health and is a non-smoker~* Subject is willing to avoid strenuous physical activity during the study~* Subject agrees to refrain from eating grapefruit or grapefruit products during the study~Exclusion Criteria:~* Subject has a history of neoplastic disease (cancer), stroke, chronic seizures, or major neurological disorder. Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases~* Subject consumes excessive amounts of alcohol or caffeinated beverages~* Subject has donated blood, had surgery or participated in another clinical study within the past 4 weeks~* Subject has a history of significant multiple and/or severe allergies to prescription or non-prescription drugs or food~* Subject has a history of hypersensitivity to metformin, sitagliptin, or sitagliptin/Metformin~* Subject is a regular user or past abuser of any illicit drugs~* Subject is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies during the study.~* Subject is a nursing mother

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: ACTIVE_COMPARATOR): Individual Tablets of 50 mg sitagliptin and 500 mg metformin
- Treatment B (Type: EXPERIMENTAL): Sitagliptin/metformin 50 mg/500 mg tablet
- Treatment C (Type: ACTIVE_COMPARATOR): Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
- Treatment D (Type: EXPERIMENTAL): sitagliptin/metformin 50 mg/1000 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Daclizumab in Patients With Chronic, Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of asthma for 6 or more months~* History of chronic persistent asthma requiring daily high dose inhaled corticosteroid for 3 or more months prior to enrollment~Exclusion Criteria:~* Patients with 10 or more pack years of smoking history or smoking within 12 months of study enrollment~* No significant disease other than asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18-90 years of age~* Diagnosis of CLI~* Infrainguinal occlusive disease, without options for revascularization~* No surgical interventions planned~* Life expectancy of 2 years~* Normal organ and marrow function~* Patients with controlled blood pressure (≤ 180/110 mmHg) and established anti-hypertensive therapy~* Established anti-platelet therapy~Exclusion Criteria:~* Poorly controlled diabetes mellitus (hemoglobin A1c \[HbA1c\] \> 10%)~* Aortoiliac disease with \> 50% stenosis~* Wounds with severity greater than Grade 3 on the Wagner Scale~* Any known failed ipsilateral revascularization within 2 weeks of enrollment~* Previous amputation of the talus, or above in the target limb~* Life-threatening ventricular arrhythmia; unstable angina; or, myocardial infarction within 4 weeks of enrollment~* Severe congestive heart failure (CHF) (i.e. New York Heart Association \[NYHA\] Stage IV)~* Receiving treatment with hematopoietic growth factors~* Infection of the involved extremity(ies)~* Active wet gangrenous tissue~* Require uninterruptible anticoagulation therapy~* Blood clotting disorder~* Cancer~* End stage renal disease requiring dialysis for more than 6 months prior to enrollment~* Pregnant or lactating~* Having received medication for thrombolytic therapy (e.g. rTPA or other enzymatic clot busters) within 30 days prior to enrollment~* Undergoing hyperbaric oxygen treatment within 2 weeks of enrollment~* Concomitant wound treatments with growth factors or tissue engineered products~* Receiving anti-angiogenic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ixmyelocel-T (Type: EXPERIMENTAL): The treatment arm of the study will receive injections of the study cellular product.
- Placebo (Type: PLACEBO_COMPARATOR): The control arm of the study will receive placebo injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue biopsy)~* Metastatic colorectal carcinoma~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~* Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer~* Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen~* Unidimensionally measurable disease~* Tumor expressing epidermal growth factor receptor (EGFr) by immunohistochemistry~* At least 2 but not more than 3 prior chemotherapy regimens for colorectal cancer~* Adequate hematologic, renal and hepatic function~Exclusion Criteria:~* Symptomatic brain metastases requiring treatment~* History or evidence of interstitial pneumonitis or pulmonary fibrosis~* Use of systemic chemotherapy or radiotherapy within 30 days prior to enrollment~* Prior epidermal growth factor receptor (EGFr) targeting therapies~* Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than a week) serum half life within 30 days before enrollment, or prior experimental or approved proteins within 3 months before enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab plus best supportive care (Type: EXPERIMENTAL): Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.
- Best Supportive Care (Type: OTHER): Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive, newly diagnosed or previously untreated POAG patients~* Patients with typical glaucomatous disc, or visual field damage~* Patient must have IOP (at 10:00 ± 1 hour)greater than 25 mm Hg~Exclusion Criteria:~* Uncontrolled glaucoma~* Distance best corrected Snellen visual acuity worse than 1/10~* Contraindications to brimonidine or dorzolamide and β-blockers~* History of lack of response (\<10% morning IOP reduction) to any medication~* Patient can not understand the instructions and adhere to medications~* Patient is a female of childbearing potential or lactating mother~* Prior surgery, past use of steroids (within 2 months)~* Severe dry eyes and use of contact lenses~* History of non-adherence~* Patients with closed angles

- Gender: ALL
- Minimum Age: 29 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Drug: Dorzolamide/Timolol (Type: ACTIVE_COMPARATOR): None
- Treatment with Brimonidine/Timolol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inflammation and Corticosteroid Responsiveness in Severe Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The final diagnosis of severe asthma will be made according to the screening steps we have set up. The definition will require the presence of one or both major criteria (treatment with continuous or near continuous oral corticosteroids and/or requirement for treatment with high dose inhaled steroids) and two minor criteria.~Patients who do not fit the criteria of severe asthma will not be entered into the study.~Age 18-60; both sexes.~For the investigation of fiberoptic bronchoscopy, other additional inclusion criteria will be imposed:~1. Post-bronchodilator FEV1 greater than 40% on the day of the bronchoscopy~2. No evidence of an exacerbation of asthma within the past 4 weeks.~3. Ability to cooperate with procedures~4. Ability to give consent~5. Current smokers, and ex-smokers with greater than 10 pack years history of smoking.~Exclusion criteria~Pregnancy or unreliable contraceptive measures in child-bearing woman. he bronchoscopist has determined the subject is clinically appropriate for bronchoscopy~-~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Severe Asthma (Type: None): Patients under Steps 4/5 of Asthma Treatment - SIGN/BTS Guidelines
- Moderate Asthma (Type: None): Asthma patients on steps 2/3 of Asthma treatment according to SIGN/BTS Guidelines
- Mild Asthma (Type: None): Asthma patients on steps 1 of asthma treatment (steroid naive).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Morphine for Postoperative Analgesia After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (age of 18 years or older);~* American Society of Anesthesiologists classification I-III;~* Scheduled to undergo unilateral TKA under combined spinal and epidural anesthesia.~Exclusion Criteria:~* Age higher than 90 years old;~* Presence of any contraindication to neuraxial block or peripheral nerve block;~* Continuous use of opioid analgesics during the last month;~* Unable to understand Numeric Rating Scale for pain evaluation or existence of language barrier;~* Severe renal insufficiency (requirement of renal replacement therapy);~* History of asthma;~* Recruited in another clinical trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Epidural morphine (Type: EXPERIMENTAL): 1. Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.~2. Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~3. Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h.
- Epidural placebo (Type: PLACEBO_COMPARATOR): 1. Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.~2. Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~3. Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Radiological suspicion of a unilocular malignant glioma with distinct ring- or garland-shaped contrast agent-accumulating tumour structures and a core of reduced intensity in the MRI (central necroses) with no significant non-staining tumour tissue (exclusion of a secondary malignant glioma).~* Indication for surgical tumour resection. If radical resection is planned, the location of the contrast agent-accumulating tumour should allow complete resection.~* First operation of the tumour, no other tumour-specific pretreatment~* Karnofsky at least 70 %~* Patient's written informed consent~* Age 18-72 years~Exclusion Criteria:~* Tumour location in the midline, basal ganglia, cerebellum or brain stem~* More than one contrast agent-accumulating lesion unrelated to the primary tumour or extracerebral metastases~* Porphyria, hypersensitivity to porphyrins~* Renal insufficiency: Creatinine \> 2.0 mg/dl~* Hepatic insufficiency: Bilirubin \> 3 mg/dl~* Quick test \< 60 %~* gamma-GT \> 70 U/I~* Malignancies other than basaliomas~* Existing or planned pregnancy or lactation, or inadequate contraception~* Simultaneous participation in another clinical trial or participation in another clinical trial in the 30 days preceding randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 5-aminolevulinic acid (Type: EXPERIMENTAL): None
- Conventional resection (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete